In conclusion, FCGR3A not only affects the prognosis of cancer patients and regulates the immune microenvironment, but also is a strong predictor for anticancer drug response, suggesting that FCGR3A may be an immunocarcinogenic molecule and can be used as a promising biomarker to provide a direction for immune-based anti-tumor strategies. The gene discussed is FCGR3A; the disease is cancer.